Landmark Study to Compare the Effectiveness of Biologic or Small Molecule Therapies in Inflammatory Bowel Disease (IBD) Receives Funding
Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel disease (IBD), which may affect as many as 3 million Americans, cost over $6 billion annually, and cause substantial patient morbidity, missed work and school, and diminished quality of life. Currently, anti-TNF therapy is considered first line treatment for moderate-to-severe IBD. However, up to 80 percent of patients do not respond or, ultimately, lose response to anti-TNF. New treatments provide additional options from which to choose, however, there are no head-to-head studies that compare these new treatments.
May 17, 2018